FDA Announces Nationwide Recall of Chlorthalidone Tablets Due to Dissolution Issues
The Food and Drug Administration announced a nationwide recall of over 13,500 bottles of chlorthalidone tablets, a blood pressure medication, due to failed dissolution specifications. The recalled product was manufactured by Inventia Healthcare Limited and is classified as a Class…
Pittsburgh, PA, September 23, 2026 — The U.S. Food and Drug Administration (FDA) has announced a nationwide recall affecting over 13,500 bottles of chlorthalidone tablets. Chlorthalidone is a medication commonly prescribed for high blood pressure.
The recall was initiated due to the product failing to meet specific dissolution specifications. Dissolution testing is a critical quality control measure that ensures a medication releases its active ingredients into the body as intended. When a drug fails these tests, it may not be absorbed properly, potentially affecting its efficacy.
The recalled chlorthalidone tablets were manufactured by Inventia Healthcare Limited. The specific lot numbers and expiration dates for the affected product were not detailed in the announcement.
The FDA has classified this recall as a Class II event. This classification indicates that the use of or exposure to a faulty product may cause temporary or medically reversible adverse health consequences. It also suggests that the probability of serious adverse health events is remote. However, healthcare providers and patients are advised to be aware of the potential implications.
Information regarding the exact distribution channels or timelines for when the affected bottles entered the market was not provided. The FDA’s announcement serves as a notification to the public and healthcare system about the recall and the potential health risks associated with the sub-potent medication.
The agency did not specify the exact nature of the adverse health consequences that could arise from the failed dissolution, beyond stating they could be temporary or medically reversible. Patients who have received prescription or over-the-counter medication are encouraged to consult with their healthcare provider if they have concerns about the chlorthalidone tablets they possess.
Further details on the recall, including any specific instructions for consumers or healthcare professionals, are typically made available through the FDA’s recall database and direct communications from the manufacturer.
Story summarized from the original created by Natalie Dreier, Cox Media Group National Content Desk on www.wpxi.com, see more information here.
Media gallery
